Abstract

BackgroundThe Dose REduction Strategies of Subcutaneous tumor necrosis factor inhibitors (TNFi) study (DRESS), a randomized controlled strategy trial (RCT) investigating disease activity guided tapering of etanercept and adalimumab compared to...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
Alfons A Den Broeder ... Frank H J Van Den Hoogen
RMD Open | VOL. 3
Alfons A Den Broeder, et. al.Alfons A Den Broeder ... Frank H J Van Den Hoogen
01 Mar 2017
AB0246 Predictive Value of a Multi-Biomarker Disease Activity Score for Successful Dose Reduction of TNF Inhibitors in Rheumatoid Arthritis: Results of the Dress Study
A Den Broeder ... C Bouman
Annals of the Rheumatic Diseases | VOL. 74
A Den Broeder, et. al.A Den Broeder ... C Bouman
01 Jun 2015
Rheumatology meeting: Efficacy, safety of biologics central focus
Maria G Tanzi
Pharmacy Today | VOL. 19
Maria G TanziMaria G Tanzi
01 Apr 2013
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
R F Van Vollenhoven ... A Van Der Maas
BMJ : British Medical Journal | VOL. 350
R F Van Vollenhoven, et. al.R F Van Vollenhoven ... A Van Der Maas
09 Apr 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers